Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Specific Language Impairment is a disorder in the development of language, despite adequate intelligence and opportunity. Genetic variants have been shown to be correlated with reduced performance on language-related tasks. A better understanding of the underlying biological pathways might help us develop more accurate identification systems and better therapies.

Q: What is Specific Language Impairment?

A: Specific language impairment is a term which is used to describe children who have problems learning to use or understand language for no obvious reason. Lots of children have problems with language development but for a lot of those it's either just the delay which they catch up as they grow a bit older, or they have some other kind of developmental problems which are causing the language impairment. The children who we investigate with specific language impairment they have persistent and quite severe language problems and no apparent problems in any other kind of developmental domains.

Q: What is the contribution of genetics to Specific Language Impairment?

A: We know that specific language impairment runs in families: if you have a brother or a sister who is affected by SLI you are about 8 or 9 times as likely to have a language problem yourself, and the same if your parents are affected, you are more likely to have language problem. We also find that twins, in pairs of twins if one is affected the other is more likely to be affected. That gives us a strong indication that there is some genetic contribution, but we don't think it's caused by a single gene mutation, we think it's combinations of common genetic variants which makes some individuals more susceptible to language problems than other individuals.

Q: What are the most important lines of research that have developed over the past 5 or 10 years?

A: We've been investigating SLI for ten years now and before we started there wasn't any molecular genetic studies done; we knew that SLI ran in families but we didn't have any idea what the genetic contributions were. When we started off, we looked at every single chromosome in a group of affected families and individuals and we narrowed it down to two regions which we believe contained genetic variants which contribute to SLI. At the moment we're looking into what those genetic variants do and how they might contribute to SLI. Over the last ten years, there's been quite a big leap in the research that's been done.

Q: Why does your line of research matter? Why should we put money into it?

A: It's a very common disorder and we don't really understand, even at the level of what is the problem that these children have, why do they have specific language problems. We're hoping that if we come at it from the genetic point of view it will give us an insight into the biological pathways that are causing these problems and the kind of developmental processes that might be underlying the disorder. We hope that this will then have a knock on effect, that we'll be able to intervene with these children earlier to develop better strategies to help them cope with their language problems.

Q: How does your research fit into Translational Medicine within the Department?

A: At the moment our research is more at the molecular level but we're hoping, once we understand these pathways, it will then lead on to translational research. Once we understand the problems that these children have, we can then combine with psychological speech therapy, that kind of research, to develop better therapies for these children. It's not in terms of diagnosing and predicting which children will be effected, it's more developing better therapies for them.

Dianne Newbury

Specific Language Impairment

Dr Dianne Newbury is looking for the genes that predispose to Specific Language Impairment, a complex genetic disorder. Two regions, located on chromosomes 16 and 19, are linked with this disorder. Interactions between several normal genetic variants and environmental factors make certain individuals more vulnerable to language problems.

This podcast presents the research done by Dr Newbury whilst working in the Nuffield Department of Medicine. Dr Newbury now works at Brookes University.

More podcasts related to Ex-faculty podcasts

Raghib Ali: INDOX Cancer Research Network

INDOX is a collaboration between Oxford and twelve leading cancer centres in India. It aims to develop effective and affordable cancer treatments in low and middle income countries, to improve the early detection of cancer, and to reduce the incidence of cancer by establishing the population specific risk factors.

Richard Antrobus: Universal Flu Vaccine

A Universal Flu Vaccine would protect against a wide range of strains of the virus. Universal vaccines target the parts of the virus that stay relatively stable and are the same between different strains of flu. The ultimate goal is to produce a vaccine that will eventually replace the normal seasonal flu jab.

Colin Baigent: Lowering cholesterol in chronic kidney disease

The SHARP study involved almost 9,500 volunteers aged 40 or over with chronic kidney disease recruited from 380 hospitals in 18 countries. Volunteers were randomly allocated to take either cholesterol-lowering therapy with a tablet containing ezetimibe 10mg daily and simvastatin 20mg daily, or matching dummy "placebo" tablets for an average of 5 years.

Colin Baigent: Wider statin use saves lives

Prof Colin Baigent discusses how the benefits outweigh the hazards of Cholesterol-lowering drugs.

Paul Bowness: Spondyloarthritis

Spondyloarthritis describes a group of arthritic illnesses where there is inflammation of the joints of the lower back. Joints become painful and stiff, and inflammation ultimately fuses the spine. A better understanding of the role of various immune components might help us better prevent it and perhaps cure it.

Vincenzo Cerundolo: Cancer immunology

The development of therapeutic vaccines is more challenging. Current lines of research include the development of antibodies blocking inhibitory T cell signals, and the characterisation of adjuvants.

Hal Drakesmith: Iron and Infection

Pathogens can escape recognition by the immune system, but they require iron from their host to grow and spread. If iron availability is high, infection can progress more rapidly. Diverting iron away from invading microbes slows their growth, giving time for our immune mechanisms to clear the infection. Manipulating iron transport might lead to new strategies to combat infections.

Christian Eggeling: Nano-immunology

Super-resolution optical microscopy allows us to study immunological processes on the molecular level. We can get new insights into how our body reacts to viral or bacterial attacks. This has the potential to help us design new drugs and developing new ways of treating diseases.

Barbara Fielding: Metabolism of Fatty Acids

Obesity puts a huge strain on health care services in the UK, with 61% of people in England being overweight. By tracing fats containing heavy atoms from meals into the blood, her aim is to learn more about fat metabolism and target treatments for the complications associated with obesity and diabetes.

Alexander Finlayson: MedicineAfrica

This podcast presents the research done by Dr Alexander Finlayson whilst working in the Nuffield Department of Medicine. Dr Finlayson now works at the Nuffield Department of Population Health.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.